News
PVLA
130.82
+2.20%
2.82
Palvella Therapeutics management to meet with Truist
TipRanks · 1d ago
Oppenheimer's fall 2026 SMID-cap ideas include four Strong Buy stocks
Seeking Alpha · 1d ago
Weekly Report: what happened at PVLA last week (0928-1002)?
Weekly Report · 2d ago
Palvella Therapeutics is Now Oversold (PVLA)
NASDAQ · 4d ago
Palvella Therapeutics: FDA Handholding Makes The Regulatory Story Stronger
Seeking Alpha · 09/29 15:52
Palvella receives third year of grant funding from FDA for QTORIN
TipRanks · 09/28 11:50
Palvella Receives Additional FDA Funding For QTORIN Rapamycin In Lymphatic Malformations
NASDAQ · 09/28 11:48
Palvella Therapeutics Receives Third Year Of Grant Funding From FDA Office Of Orphan Products Development For Phase 3 SELVA Trial And Ongoing Open-Label Extension Study Of QTORIN 3.9% Rapamycin Anhydrous Gel For Treatment Of Microcystic Lymphatic Malformations
Benzinga · 09/28 11:35
Weekly Report: what happened at PVLA last week (0921-0925)?
Weekly Report · 09/28 09:25
Palvella Therapeutics Is Maintained at Buy by Chardan Capital
Dow Jones · 09/21 14:06
Palvella Therapeutics Price Target Maintained With a $240.00/Share by Chardan Capital
Dow Jones · 09/21 14:06
Palvella Therapeutics transferred with Buy rating at Chardan
TipRanks · 09/21 10:20
Weekly Report: what happened at PVLA last week (0914-0918)?
Weekly Report · 09/21 09:25
Weekly Report: what happened at PVLA last week (0907-0911)?
Weekly Report · 09/14 09:26
Mizuho Securities Keeps Their Buy Rating on Palvella Therapeutics (PVLA)
TipRanks · 09/10 14:55
*Palvella Therapeutics Appoints James R. Treat as Chief Medical Officer
Dow Jones · 09/09 11:30
Weekly Report: what happened at PVLA last week (0831-0904)?
Weekly Report · 09/07 09:24
Palvella Therapeutics Director Makes Eye-Catching Insider Move in Latest Stock Transaction
TipRanks · 09/05 02:06
Analysts Are Bullish on Top Healthcare Stocks: Palvella Therapeutics (PVLA), Protagonist Therapeutics (PTGX)
TipRanks · 09/01 00:30
Palvella Completes Rolling NDA For QTORIN Rapamycin In Microcystic Lymphatic Malformatios
NASDAQ · 08/31 15:31
More
Webull provides a variety of real-time PVLA stock news. You can receive the latest news about Palvella Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About PVLA
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The Company is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its QTORIN product candidates are developed to accommodate the cargo at high concentrations in order to drive sufficient drug to its target deep in the epidermis and dermis. The Company's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is being evaluated in the Phase III SELVA clinical trial in microcystic lymphatic malformations and the Phase II TOIVA clinical trial in cutaneous venous malformations.